Sanofi (NASDAQ:SNY)
| Market Cap | 103.35B-15.3% |
| Revenue (ttm) | 48.92B+13.4% |
| Net Income | 3.96B-56.6% |
| EPS | 0.48-87.2% |
| Shares Out | 2.40B |
| PE Ratio | 23.29 |
| Forward PE | 9.84 |
| Dividend | $4.17(10.94%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 4,264,887 |
| Open | 42.34 |
| Previous Close | 42.24 |
| Day's Range | 42.17 - 43.14 |
| 52-Week Range | 39.07 - 52.68 |
| Beta | 0.30 |
| Analysts | Hold |
| Price Target | 49.00(+13.61%) |
| Earnings Date | Oct 30, 2026 |
Sanofi has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
Unlock SNY’s Insider ScoreAbout SNY
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Oct 30, 2026Earnings report
Ask Barron about SNY
$SNY stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of SNY by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Alan ArmstrongSenate / R | Purchase$15.00K – $50.00K | Mar 30, 2026 |
Recently reported changes in SNY holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SNY's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SNY Estimated quarterly lobbying spending
Source: U.S. Senate LDA
SNY Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New SNY patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SNY from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SNY
| ETF | Est. Holding Size |
|---|---|
| AVDEAvantis International Equity ETF | $43.97M |
| AFTYPacer CSOP FTSE China A50 ETF | $41.22M |
| FENIFidelity Enhanced International ETF | $38.00M |
| PPHVanEck Pharmaceutical ETF | $34.46M |
| FVLFirst Trust Value Line 100 Exchange-Traded Fund | $33.52M |
| FVDFirst Trust Value Line Dividend Index Fund | $33.52M |
Estimated from each fund’s disclosed top holdings × AUM
SNY Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SNY’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score